[
  {
    "ts": "2025-12-02T13:45:00+00:00",
    "headline": "Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development",
    "summary": "Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M",
    "url": "https://finance.yahoo.com/news/palisade-bio-strengthens-clinical-leadership-134500234.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f3f6fa9f-6170-36f2-a258-f8693a05bd5a",
      "content": {
        "id": "f3f6fa9f-6170-36f2-a258-f8693a05bd5a",
        "contentType": "STORY",
        "title": "Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development",
        "description": "",
        "summary": "Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M",
        "pubDate": "2025-12-02T13:45:00Z",
        "displayTime": "2025-12-02T13:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d4f36a2101d324cba1c551001ca4ba4d",
          "originalWidth": 690,
          "originalHeight": 178,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hvYCpPkns04.Y3xoR9PLLw--~B/aD0xNzg7dz02OTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d4f36a2101d324cba1c551001ca4ba4d.cf.webp",
              "width": 690,
              "height": 178,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nGF6N3FJGxYkCK1j5m3AMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d4f36a2101d324cba1c551001ca4ba4d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/palisade-bio-strengthens-clinical-leadership-134500234.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/palisade-bio-strengthens-clinical-leadership-134500234.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PALI"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]